Balkrishna Industries Ltd (BALKRISIND) Q1 FY27 Results Analysis: PAT Jumps 56%, Revenue Surges 25%
Balkrishna Industries Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 3,455.27 Cr (+25.19% YoY) and PAT growth of +56.35% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | July 29, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 3,455.27 Cr (+25.19% YoY) |
| PAT (Q1) | Rs. 450.77 Cr (+56.35% YoY) |
| EBITDA margin | 21.54% (+320 bps YoY) |
| EPS (Q1) | Rs. 23.32 (+56.41% YoY) |
| Market cap | Rs. 40,354.46 Cr |
| CMP | Rs. 2,085.00 |
Quarter Snapshot
Balkrishna Industries delivered a strong Q1 with 25% revenue growth and 56% PAT growth, driven by demand recovery in Europe and North America and price hikes. EBITDA margin expanded 320 bps YoY to 21.54%, though raw material cost pressure caused slight QoQ compression. The interim dividend and strong coverage ratios reflect financial health, but margin remains below the medium-term target.
Key Investment Insights
Key Positives
- Consolidated revenue grew 25% YoY to Rs.3,455 Cr, the highest Q1 on record.
- PAT grew 56% YoY to Rs.451 Cr, with EPS rising to Rs.23.32 from Rs.14.91.
- EBITDA margin expanded 320 bps YoY to 21.54%, driven by operating leverage and cost management.
- Interim dividend of Rs.4 per share declared, signalling confidence.
- Debt Service Coverage Ratio improved to 4.87x from 3.55x QoQ, indicating strong coverage.
Risk Factors
- Raw material cost increased 49% YoY, outpacing revenue growth, causing QoQ margin compression of 28 bps.
- Debt-equity ratio rose to 0.41x from 0.37x QoQ as capex spending continued, and current ratio fell below 1.0x to 0.97x.
- EBITDA margin of 21.54% remains below the medium-term target of 23-25%, partly due to raw material pressure.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.